title: Dose-escalated radiation therapy with and without short-course androgen deprivation for intermediate-risk prostate cancer.
abstract: OBJECTIVE
  To investigate outcomes in intermediate-risk (IR) prostate cancer patients receiving dose-escalated external beam radiation therapy (RT) with or without short-course androgen deprivation (ADT).
  
  
  METHODS
  This study comprised of 203 patients with IR prostate cancer who were treated at a single institution to a dose of 7,560 cGy or more between 2003-2010. Of these, 62 (30.5%) patients received ADT. Biochemical recurrence, distant metastatic-free survival, prostate cancer-specific survival, and overall survival were analyzed using the Kaplan-Meier method.
  
  
  RESULTS
  The median follow-up was 62 months and the median duration of ADT was 6 months. The 6-year biochemical control was 89.2% for those receiving RT plus ADT versus 76.7% in those receiving RT alone (p=0.02). There were no differences between the two groups regarding distant metastatic-free survival, prostate cancer-specific survival, and overall survival (respective p-values of 0.91, 0.50, 0.67).
  
  
  CONCLUSIONS
  Dose-escalated RT and short-course ADT results in improved biochemical outcomes for IR prostate cancer.
authors: Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, NY, U.S.A. Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, U.S.A. David.schreiber@va.gov.
authors: David
authors: D
authors: Schreiber
authors: Department of Radiation Oncology, UF Orlando Health Center, Orlando, FL, U.S.A.
authors: Justin
authors: J
authors: Rineer
authors: Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, NY, U.S.A. Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, U.S.A.
authors: Aparna
authors: A
authors: Surapaneni
authors: Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, NY, U.S.A. Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, U.S.A.
authors: Elliot
authors: E
authors: Navo
authors: Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, NY, U.S.A. Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, U.S.A.
authors: Manuj
authors: M
authors: Agarwal
authors: Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, NY, U.S.A.
authors: Emmanuel
authors: E
authors: Nwokedi
authors: Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, NY, U.S.A. Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, U.S.A.
authors: Marvin
authors: M
authors: Rotman
authors: Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, NY, U.S.A. Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, U.S.A.
authors: David
authors: D
authors: Schwartz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012306:Risk
chemical_list: D000726:Androgen Antagonists
keywords: Radiation therapy; androgen deprivation; dose escalation; intermediate risk prostate cancer